Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Castle Biosciences Inc
CSTL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$33.19
-1.18
-3.43%
Últ. Act.: Oct 22, 4:00 PM
$33.19
-1.18
-3.43%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Ganancias:
Beneficios de Q3 2026 dentro de 13 días de ahora en jue nov 5th, después del cierre del mercado
Castle Biosciences Financials
Castle Biosciences (CSTL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 146.67 percent decrease over earnings of $0.15 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $340.000M-$350.000M to $345.000M-$355.000M vs $345.734M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million to $345.000 million-$355.000 million vs $345.734 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 145 percent decrease over losses of $(0.20) per share from the same period last year.
Benzinga Newsdesk
Castle Biosciences Q4 Earnings Assessment
Benzinga Insights
